The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist
Citations Over TimeTop 10% of 2010 papers
Abstract
Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and evaluated for their potential as inhaled ultralong-acting bronchodilators. Determination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference beta(2)-adrenoceptor agonists. Further assessment with an in vitro superfused electrically stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compounds. From these studies the 5,6-diethylindan analogue indacaterol 1c was shown to possess a unique profile of combining a rapid onset of action with a long duration of action. Further in vivo profiling of 1c supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compound being selected as a development candidate.
Related Papers
- → Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium(2010)89 cited
- → Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study(2013)73 cited
- → Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD(2016)6 cited
- → P232 Once-daily co-administration of glycopyrronium and indacaterol via Breezhaler®device improves lung function and symptoms in patients with COPD versus indacaterol alone: the GLOW6 study(2013)2 cited
- → A novel ultra long-acting bronchodilator——indacaterol(2010)